Skip to main content

Stephen Joseph Balevic

Associate Professor of Pediatrics
Pediatrics, Rheumatology
2301 Erwin Rd, Durham, NC 27710
2301 Erwin Rd, Durham, NC 27710

Overview


I am an Adult and Pediatric Rheumatologist and care for patients with a wide variety of autoimmune and rheumatic diseases, including: systemic lupus, rheumatoid arthritis, juvenile arthritis, vasculitis, and sarcoidosis, among others. I have a special interest in using musculoskeletal ultrasound to optimize diagnosis and treatment decisions at the bedside.

I am also a clinical researcher at the Duke Clinical Research Institute (DCRI). My research interests are in clinical trials and precision medicine through population pharmacokinetic/pharmacodynamic modeling. I obtained my PhD in Pharmaceutical Sciences from the UNC Eshelman School of Pharmacy. I serve as the principal investigator on several grants studying hydroxychloroquine and azathioprine pharmacokinetics and exposure-response in lupus, as well as principal investigator or co-investigator for several clinical trials at the DCRI. Additionally, I am an Assistant Scientific Director for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry- the largest registry of children with rheumatic diseases in North America.

Current Appointments & Affiliations


Associate Professor of Pediatrics · 2022 - Present Pediatrics, Rheumatology, Pediatrics
Associate Professor of Medicine · 2022 - Present Medicine, Rheumatology and Immunology, Medicine
Member in the Duke Clinical Research Institute · 2018 - Present Duke Clinical Research Institute, Institutes and Centers

In the News


Published September 22, 2020
DCRI Launches First Direct-to-Family Study

View All News

Recent Publications


Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity.

Journal Article Clin Pharmacokinet · November 17, 2025 BACKGROUND: Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body w ... Full text Link to item Cite
View All Publications

Recent Grants


PTN 3.0 Task Order #2_ BPCA Pediatric Drug Development Clinical Trial Infrastructure

ResearchProject Leader · Awarded by National Institutes of Health · 2025 - 2030

Induced Suppression of Platelet Activity in Aneurysmal SAH Management-2 (iSPASM-2)

Clinical TrialInvestigator · Awarded by National Institutes of Health · 2025 - 2030

Pharmacokinetic Modeling to Optimize Dosing in Pediatric Rheumatic Diseases

ResearchPrincipal Investigator · Awarded by Thrasher Research Fund · 2025 - 2028

View All Grants

Education, Training & Certifications


University of North Carolina, Chapel Hill · 2022 Ph.D.
Duke University, School of Medicine · 2018 M.H.S.
Marshall University · 2010 M.D.